This study uses cryo-EM to reveal how the SARS-CoV-2 RTC discriminates between natural NTPs and the antiviral remdesivir triphosphate, providing insights for antiviral design.

bioRxiv · May 20, 2022Biophysics

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants

J. Pitts, J. Li, J. Perry, V. Du Pont, N. Riola, L. Rodriguez, X. Lu, C. Kurhade, X. Xie, G. Camus, S. Manhas, R. Martin, P.-Y. Shi, T. Cihlar, D. P. Porter, , J. P. Bilello

This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.

bioRxiv · Feb 9, 2022Microbiology

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir

M. Götte, C. J. Gordon, H. W. Lee, E. P. Tchesnokov, J. K. Perry, J. Y. Feng, J. P. Bilello, D. P. Porter

This study investigates how remdesivir's antiviral activity varies across RNA viruses by analyzing its incorporation and inhibition mechanisms in different polymerases.

bioRxiv · Oct 14, 2021Biochemistry

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

A. Schafer, D. R. Martinez, J. J. Won, F. R. Moreira, A. J. Brown, K. L. Gully, R. Kalla, K. Chun, V. Du Pont, D. Babusis, J. Tang, E. Murakami, R. Subramanian, K. T. Barrett, B. J. Bleier, , T. P. Sheahan

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

bioRxiv · Sep 13, 2021 · PreprintMicrobiology

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents

T. N. D. Do, K. Donckers, L. Vangeel, A. K. Chatterjee, P. A. Gallay, M. D. Bobardt, J. P. Bilello, T. Cihlar, S. De Jonghe, J. Neyts, D. Jochmans

This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.

bioRxiv · Mar 25, 2021Microbiology

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

P.-Y. Shi, X. Xie, A. E. Muruato, X. Zhang, K. G. Lokugamage, C. R. Fontes-Garfias, J. Zou, J. Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.-T. K. Tseng, S. Makino, V. D. Menachery, J. P. Bilello

This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.

Nature Communications · Oct 15, 2020Peer-reviewedMicrobiology

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility

J. A. Plante, Y. Liu, J. Liu, H. Xia, B. A. Johnson, K. G. Lokugamage, X. Zhang, A. E. Muruato, J. Zou, C. R. Fontes-Garfias, D. Mirchandani, D. Scharton, J. P. Bilello, Z. Ku, Z. An, , P.-Y. Shi

This study shows the D614G mutation in SARS-CoV-2 increases viral replication and upper respiratory tract viral loads but does not reduce vaccine efficacy or antibody neutralization.

bioRxiv · Sep 1, 2020Microbiology

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology